AgenusHealth, Investment, Medical, Science
BEST is envisioned as a way to democratize financing through targeted investments for specific therapeutic drug products. Tokenization will enable accredited investors the opportunity to invest directly in a single asset, Agenus’ anti-PD-1 antibody (AGEN2034), while preserving shareholder equity.
B.E.S.T is a revolutionary tool enabling accredited investors to invest in specific late stage products:
- B.E.S.T will be built upon blockchain technology, B.E.S.T is NOT a cryptocurrency
- The first B.E.S.T is offered for a late stage product, AGEN2034, a PD-1 antibody
- All PD-1 molecules that entered late stage development have received FDA approval. AGEN2034, Agenus’ PD-1 is in late stage development for patients with advanced cervical cancer